STOCK TITAN

Royalty Pharma (RPRX) EVP gets 8,252 shares, gifts LP interests

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Royalty Pharma plc executive Urist Marshall reported two insider equity movements. He received 8,252 Class A Ordinary Shares as an exempt award tied to Equity Performance Awards and indirectly made a bona fide gift of 3,000 limited partnership interests exchangeable into 30,000 Class A shares. He also holds Class A shares indirectly through an IRA and Class E Ordinary Shares that are exchangeable into 1,356,528 Class A shares, subject to vesting conditions.

Positive

  • None.

Negative

  • None.
Insider Urist Marshall
Role EVP, Research & Investments
Type Security Shares Price Value
Gift LP interests in RPI US Partners 2019, LP F2, F3 3,000 $0.00 $0.00
Grant/Award Class A Ordinary Shares F1 8,252 $0.00 $0.00
holding Class A Ordinary Shares -- -- --
Holdings After Transaction: LP interests in RPI US Partners 2019, LP — 244,412 shares (Indirect, By Sandy Lamm LLC); Class A Ordinary Shares — 8,252 shares (Direct); Class A Ordinary Shares — 19,020 shares (Indirect, By IRA)
Footnotes (3)
  1. F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
  2. F2. No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.
  3. F3. Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Class A shares acquired 8,252 shares Exempt acquisition on August 5, 2026 in connection with settlement of Equity Performance Awards
LP interests gifted 3,000 interests Bona fide gift of RPI US Partners 2019, LP interests on August 7, 2026, held indirectly via Sandy Lamm LLC
Underlying Class A shares from gifted LP interests 30,000 shares Class A Ordinary Shares underlying 3,000 RPI US LP interests, each exchangeable into ten Class B Interests then one Class A share
RPI US LP interests after gift 244,412 interests Limited partnership interests in RPI US Partners 2019, LP indirectly held after the reported gift
Indirect Class A shares via IRA 19,020 shares Class A Ordinary Shares indirectly owned through an IRA as of August 5, 2026
Potential Class A shares from Class E Ordinary Shares 1,356,528 shares Class A Ordinary Shares exchangeable from Class E Ordinary Shares of Holdings, subject to vesting conditions
Equity Performance Awards financial
"Reflects the exempt acquisition ... in connection with the settlement of Equity Performance Awards."
bona fide gift financial
"Transaction code G is described as a bona fide gift of derivative securities."
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Rule 16b-3 regulatory
"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3."
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Class E Ordinary Shares financial
"The Reporting Person holds Class E Ordinary Shares of Holdings exchangeable into 1,356,528 Class A Ordinary Shares."
Exchange Agreement financial
"Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020."
A written deal in which two parties agree to swap assets, securities or obligations under set terms—think of it as a formal swap or trade contract. For investors it matters because such agreements can change who owns what, alter a company’s capital structure, affect future cash flows or dilute existing shares, and therefore influence value and risk in a straightforward, contract-driven way.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What Class A share award did Royalty Pharma (RPRX) executive Urist Marshall report?

He acquired 8,252 Class A Ordinary Shares on August 5, 2026 as an exempt award under Rule 16b-3 related to the settlement of Equity Performance Awards, increasing his directly held Class A position to 8,252 shares.

What gift transaction involving Royalty Pharma (RPRX) securities did Urist Marshall disclose?

He reported a bona fide gift of 3,000 limited partnership interests in RPI US Partners 2019, LP on August 7, 2026. Each interest is exchangeable into ten Class B Interests and then into one Class A Ordinary Share, representing 30,000 potential shares.

How many RPI US Partners 2019, LP interests does Urist Marshall hold after the gift reported for RPRX?

After the gift, he indirectly holds 244,412 limited partnership interests in RPI US Partners 2019, LP through Sandy Lamm LLC. Each interest is exchangeable into Class B Interests in Holdings and ultimately Class A Ordinary Shares at no additional value.

What indirect Class A holdings through an IRA are associated with Urist Marshall in Royalty Pharma (RPRX)?

He reports indirect ownership of 19,020 Royalty Pharma Class A Ordinary Shares held "By IRA" as of August 5, 2026. These are separate from his directly held shares and from partnership and other exchangeable interests.

What potential additional Royalty Pharma (RPRX) shares are linked to Urist Marshall’s Class E Ordinary Shares?

He holds Class E Ordinary Shares of Holdings that are exchangeable into 1,356,528 Class A Ordinary Shares. These Class E shares are subject to vesting conditions, so the related Class A shares are potential, not yet delivered, equity exposure.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Urist Marshall

(Last)(First)(Middle)
C/O ROYALTY PHARMA PLC
110 EAST 59TH STREET

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Research & Investments
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Shares08/05/2026A8,252(1)A$08,252D
Class A Ordinary Shares19,020IBy IRA
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
LP interests in RPI US Partners 2019, LP(2)08/07/2026G3,000 (3) (3)Class A Ordinary Shares30,000$0244,412IBy Sandy Lamm LLC
Explanation of Responses:
1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
2. No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.
3. Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Remarks:
In addition to the Class A Ordinary Shares disclosed above, the Reporting Person holds Class E Ordinary Shares of Holdings exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of Holdings are subject to vesting conditions.
/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)